Mitsubishi Chemical to boost drug-capsule capacity: Nikkei
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[TOKYO] Mitsubishi Chemical Holdings Corp will invest 20 billion yen (S$249.66 million) over the next five years to increase the production capacity of drug capsules by 70 per cent, the Nikkei reported, without citing anyone.
Mitsubishi Chemical will increase the number of production lines in the US, Europe and Japan, according to the newspaper.
The company will boost its lineup of plant-based drug capsules to meet demand from customers in the Middle East, where pork-based gelatin products face resistance on religious grounds, the newspaper said.
BLOOMBERG
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
